他汀类药物对转移性肾细胞癌生存结局的影响
Effects of statins on survival outcomes in patients with metastatic renal cell carcinoma
高石亮 1贺晓奇 2郑慧杰 1杨迪 3余明主1
作者信息
- 1. 联勤保障部队第九○八医院泌尿外科(南昌 330000)
- 2. 联勤保障部队第九○八医院肾内科(南昌 330000)
- 3. 联勤保障部队第九○八医院骨科(南昌 330000)
- 折叠
摘要
目的 评估他汀类药物联合索拉非尼(SRF)治疗对转移性肾细胞癌(mRCC)患者生存结局的影响.方法 回顾性分析2019年11月至2023年11月联勤保障部队第九○八医院诊治的mRCC患者临床资料.根据是否使用他汀类药物分为他汀组和非他汀组,比较两组主要结局指标总生存期(OS)、次要结局指标无进展生存期(PFS)、客观反应率(ORR)和疾病控制率(DCR)差异.结果 研究共纳入患者80例,他汀组27例和非他汀组53例.两组部分缓解、疾病稳定、疾病进展和DCR比较差异无统计学意义(P＞0.05);他汀组完全缓解和ORR显著高于非他汀组(P＜0.05).Kaplan-Meier分析表明,与非他汀组比较,他汀组中位PFS和OS均延长,其中两组中位PFS差异有统计学意义(P＜0.05).安全性方面,两组患者的其他不良反应发生率差异无统计学意义(P＞0.05).结论 他汀类药物联合SRF治疗方案可提高mRCC患者ORR和DCR,延长患者中位PFS和OS.
Abstract
Objective To assess the impact of statins combined with sorafenib(SRF)therapy on survival outcomes in patients with metastatic renal cell carcinoma(mRCC).Methods Clinical data of mRCC patients treated in the 908th Hospital of the Joint Security Force from November 2019 to November 2023 were retrospectively analyzed.They were categorized into statin group and non-statin group according to whether they used statins or not,and the differences in the primary endpoint of overall survival(OS),secondary endpoints of progression-free survival(PFS),objective response rate(ORR),and disease control rate(DCR)were compared between the two groups.Results A total of 80 patients were included in the study,with 27 in the statin group and 53 in the non-statin group.There were no statistically significant differences in partial remission,stable disease,disease progression,and DCR between the two groups(P＞0.05);complete remission and ORR were significantly higher in the statin group than in the non-statin group(P＜0.05).Kaplan-Meier analysis showed that,compared with the non-statin group,the median PFS and OS of the statin group were prolonged,and the difference in median PFS between the two groups was statistically significant(P＜0.05).In terms of safety,the incidence of other adverse events was similar in both groups(P＞0.05).Conclusion Statins combined with SRF treatment regimen can improve ORR and DCR and prolong median PFS and OS in patients with mRCC.
关键词
转移性肾细胞癌/他汀类药物/生存结局/总生存期/无进展生存期/客观反应率/疾病控制率Key words
Metastatic renal cell carcinoma/Statins/Survival outcomes/Overall survival/Progression-free survival/Objective response rate/Disease control rate引用本文复制引用
出版年
2024
NETL
NSTL
万方数据